View printer-friendly version

Download PDF

Emergent BioSolutions Delivers over 3 Million Doses of BioThrax(R) to U.S. Department of Health and Human Services for Strategic National Stockpile

–Delivery represents approximately $75 million of revenue for 4Q 2006; Company on track to deliver remaining 1 million doses in 1Q 2007–

GAITHERSBURG, Md.–(BUSINESS WIRE)–Dec. 14, 2006–Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has successfully completed the 4Q 2006 deliveries of over three million doses of BioThrax(R) (Anthrax Vaccine Adsorbed), the only FDA licensed anthrax vaccine, to the Department of Health and Human Services (HHS) for placement into the nation’s strategic national stockpile (SNS). The delivery of these doses, made under a May 2006 modified contract with HHS, represents 4Q 2006 revenue of approximately $75 million.

Under the modified contract, the company is required to complete delivery of a total of five million doses of BioThrax(R) to HHS prior to May 31, 2007 for a fixed price of $120 million. Since the contract modification, the company has delivered approximately four million doses of BioThrax(R) and expects to deliver the balance during 1Q 2007. Including the 4Q 2006 deliveries, the company has now supplied over nine million doses of BioThrax(R) to HHS for inclusion in the SNS.

“Over the past five years, we have consistently demonstrated our ability to meet our contractual obligations to deliver critically needed countermeasures to the U.S. Government for placement into the Strategic National Stockpile,” said Robert G. Kramer, president and chief executive officer of the company’s biodefense operations. “Our success is directly attributable to our dedicated employees who exhibit a deep commitment to these principles every day in assuring the continued successful manufacture of the only FDA approved vaccine against anthrax.”

The company’s initial deliveries to HHS were pursuant to a May 2005 supply agreement under which the company agreed to supply an initial five million doses of BioThrax(R) for placement into the SNS for a fixed price of $123 million. The company successfully delivered all five million doses by February 2006, seven months ahead of schedule. The SNS, which is administered by the U.S. Centers for Disease Control and Prevention, comprises large quantities of medicine and medical supplies to protect the American public if there is a public health emergency (terrorist attack, flu outbreak, earthquake) severe enough to cause local supplies to run out.

“We are proud to play a vital role in the strategic defense of the United States and the protection of its citizens from the threat of an anthrax attack,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “We welcome the opportunity to continue to work closely with the Department of Health and Human Services to meet the strategic biodefense requirements of the Government.”

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. Immunobiotics are vaccines and immune globulins that induce or assist the body’s immune system to prevent or treat disease. The company’s biodefense business is focused on developing and commercializing immunobiotics for use against biological agents that are potential weapons of bioterrorism. The company’s commercial business is focused on developing immunobiotics for use against infectious diseases with significant unmet or underserved medical needs. More information on the company is available at www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions are forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements, including our plans for future sales of BioThrax(R); our plans to pursue label expansions and improvements for BioThrax(R); our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; our ongoing and planned development programs; preclinical studies and clinical trials; our ability to identify and acquire or in license products and product candidates that satisfy our selection criteria; the potential benefits of our existing collaboration agreements and our ability to enter into selective additional collaboration arrangements; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property portfolio; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company’s Registration Statement on Form S-1 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.